Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis Nov 30, 2022
Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022 Oct 28, 2022
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022 Oct 27, 2022
Aurinia Launches Campaign Aimed at Educating and Motivating People with Lupus Nephritis to Prioritize Their Kidney Health and Take Action Oct 25, 2022
Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022 Sep 20, 2022
Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis Sep 19, 2022
